Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Clinical Trial
NCT01186861Last updated: 12/5/2025
4503.T
Astellas Pharma Inc.
